Check patentability & draft patents in minutes with Patsnap Eureka AI!

Novel peptide

A fusion peptide and functional peptide technology, applied in the active field of functional peptides, can solve the problems of skin thinning, dullness, spots, etc., and achieve the effects of improving wrinkles and sagging, skin firming, and promoting adhesion

Inactive Publication Date: 2014-10-01
ROHTO PHARM CO LTD
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, when the adhesion between the basement membrane and the cells is weakened, the overall health of the skin may become poor, which may lead to thinning of the epidermis. In addition, the movement of various factors through the basement membrane is hindered, resulting in poor metabolism. At the same time, it is easy to cause spots (accumulation of melanin) or dullness, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel peptide
  • Novel peptide
  • Novel peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0109] Example 1: Preparation of GRIRVL (Gly-Arg-Ile-Arg-Val-Leu) Peptide

[0110] (1) Synthesis of peptides:

[0111] The GRIRVL peptide was synthesized by a solid-phase synthesis method using the Fmoc method using an automatic peptide synthesizer (manufactured by Shimadzu Corporation: PSSM8). The specific procedure is as follows: First, after the C-terminal of Fmoc-Leu-OH is bound to the resin for solid-phase synthesis, the protective group (Fmoc) is removed by piperidine treatment, and then, after neutralizing and washing the resin, the Fmoc-Val-OH was introduced into the N-terminus of Leu. Next, the protecting group (Fmoc) was removed by piperidine treatment, and after the resin was neutralized and washed again, Fmoc-Arg(Pmc)-OH was introduced into the N-terminal of Val. Next, the protecting group (Fmoc) was removed by piperidine treatment, and the resin was neutralized and washed again, and then Fmoc-Ile-OH was introduced into the N-terminal of Arg. Next, the protectin...

Embodiment 2

[0114] Example 2: Measuring Gene Expression Using Microarrays

[0115] Dulbecco's modified MEM (DMEM) (GIBCO) containing 10% fetal bovine serum (FBS) was used in 12-well microplates at 3.0 × 10 4 cells / cm 2 Normal human dermal fibroblasts (KF-4009; Kurashiki (クラボウ)) were inoculated at a cell density of . 24 hours after inoculation, it was exchanged with DMEM containing the GRIRVL peptide prepared in Example 1 above at a specified concentration (0.5 mg / ml or 1 mg / ml), and cultured for 48 hours. In addition, as a control (no treatment group), wells exchanged with DMEM not containing the test peptide were prepared, and cultured for 48 hours in the same manner. Next, using RNeasy Mini Kit (QIAGEN) and QIA shredder (QIAGEN), RNA was extracted from each of the fibroblasts of the GRIRVL peptide-treated group and the untreated group. For each extracted RNA, the gene expression profiles of the GRIRVL peptide-treated group and the non-treated group were compared using the human versi...

Embodiment 3

[0128] Example 3: Evaluation of collagen production promoting effect

[0129] Using Dulbecco's modified MEM (DMEM) (GIBCO) containing 10% fetal bovine serum (FBS) in a 96-well microplate at 6.25 × 10 4 cells / cm 2Normal human dermal fibroblasts (KF-4009; Kurabo) were seeded at a cell density of . 24 hours after inoculation, it was exchanged with DMEM containing the GRIRVL peptide prepared in Example 1 at the indicated concentration. In addition, as a control (no treatment group), wells exchanged with DMEM not containing the test peptide were also prepared. After culturing the GRIRVL peptide-containing group and the non-treatment group for about 48 hours, the culture supernatant was collected and used for type I collagen ELISA. Anti-type I collagen antibody (Rabbit) (manufactured by ROCKLAND) was used for the primary antibody reaction, Histofine simple stain MAX-PO(R) (Rabbit) (manufactured by NICHIREI) was used for the secondary antibody reaction, and type I of the culture s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel peptide. The object of the invention is to provide a new material in a biological body capable of promoting the integrin or the collagen. The new material is constituted by the peptide formed by the amino acid sequence expressed by the following formula (I)Gly-Arg-Ile-Arg-Val-Leu(SEQ ID NO:1),or the amino acid sequence is provided with one or a plurality of peptides or the ramification of the peptides, or the salts additionally provided with / missing / or replaced by the amino acids.

Description

technical field [0001] An object of the present invention is to provide a novel substance having an effect of promoting expression of integrin, collagen, etc. in a living body. Furthermore, the present invention also relates to a method for increasing the activity of a functional peptide such as a growth factor or a hormone by utilizing cell adhesion via a cell adhesion factor such as an integrin, and the like. Background technique [0002] In living tissue, cells and extracellular matrix interact through adhesion and transmit signals inside the cells to induce or repress various factors such as genes and proteins, thereby performing cytoplasmic control such as cell differentiation and proliferation and secretion of metabolites. In addition, the extracellular matrix itself such as collagen strengthens and stabilizes the grid-like three-dimensional structure of collagen fiber bundles by adhering to cells, and maintains the tension and elasticity of the skin. Therefore, when...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K5/103C07K19/00A61K8/64A61K38/08A61K38/07A61Q19/00A61P17/00A23L1/29A23K1/16A23K20/147A23L33/00
Inventor 熊泽益德池山芳史黑濑沙予中田温子本多裕之加藤竜司
Owner ROHTO PHARM CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com